{"id":12145,"date":"2021-04-20T00:40:17","date_gmt":"2021-04-19T22:40:17","guid":{"rendered":"https:\/\/disturbmenot.co\/?p=12145"},"modified":"2021-04-20T00:40:17","modified_gmt":"2021-04-19T22:40:17","slug":"new-insomnia-drug-pends-fda-approval","status":"publish","type":"post","link":"https:\/\/disturbmenot.co\/new-insomnia-drug-pends-fda-approval\/","title":{"rendered":"A New Revolutionary Insomnia Drug Pends FDA Approval"},"content":{"rendered":"
This January, the biopharmaceutical company <\/span>Idorsia Pharmaceuticals Ltd<\/span><\/a>. submitted an application to the<\/span> Food and Drug Administration (FDA)<\/b> for the assessment of <\/span>Daridorexant <\/b>\u2014 the company\u2019s insomnia treatment drug.\u00a0<\/span><\/p>\n Daridorexant is an absolute novelty in the market because of its effective but short-term action. Specifically, <\/span>it leaves the patient\u2019s system quickly, enabling them to function without the inconvenient <\/b>next-day drowsiness<\/b><\/a> caused by other <\/span>sleep medication<\/span>.\u00a0<\/span><\/p>\n While the traditional insomnia medication is usually a Central Nerve System depressor, Daridorexant is a so-called <\/span>dual orexin receptor antagonist<\/span><\/a>.\u00a0<\/span><\/p>\n This means that it temporarily deactivates the overactive wakefulness by disabling orexin neuropeptides\u2019 action \u2014 substances responsible for promoting alertness.\u00a0<\/span><\/p>\n Today, daytime sleepiness and withdrawal effects are the main reasons why insomniacs reach for the best <\/span>natural sleep aids<\/span><\/a> instead of prescription pills. But this will change if Daridorexant finds its place on the shelves in pharmacies across the US.\u00a0<\/span><\/p>\n Namely, during clinical studies, this revolutionary drug showed none of these <\/span>residual effects<\/span><\/a>.\u00a0<\/span><\/p>\n The side effects, the efficacy, and safety of Daridorexant were tested in two clinical trials and a developmental program \u2014 all part of the<\/span> exhaustive <\/span>New Drug Application (NDA) dossier<\/b> submitted to the FDA.\u00a0<\/span><\/p>\n